Key takeaway: The investor presentation from Dr. Agarwal's Health Care Limited detailed the company's unaudited financial results for the quarter ended June 30, 2026. The presentation reported a revenue from operations of ₹614 crore, reflecting a year-on-year growth rate of 26.0%. EBITDA was reported at ₹177 crore, with a growth rate of 25.2%, while profit after tax reached ₹55 crore, marking a 44.6% increase. The company served over 882,000 patients and performed more than 91,000 surgeries during the quarter. Management highlighted the addition of 18 new facilities, bringing the total to 304 across India and Africa. The presentation emphasized the company's strong market position as India's largest eye care services chain and its commitment to clinical excellence and innovation in eye care treatments. The document also included a disclaimer regarding the information provided, stating it was for general informational purposes only.

Key takeaway: During the earnings conference call held on May 21, 2026, management reported that Dr. Agarwal's Healthcare Limited achieved a significant milestone by crossing INR 2,000 crores in revenue for the first time in its history, with total income for FY '26 reaching INR 2,125 crores, a 20.9% increase year-on-year. The company also reported a profit after tax of INR 168 crores, reflecting a 52.4% growth. In Q4 FY '26, total income was INR 577 crores, up 21.2% year-on-year. Management highlighted the opening of 19 new facilities in the quarter, expanding their network to 269 facilities. The company emphasized its focus on clinical excellence, with high-end cataract surgeries growing significantly. Management set a goal to commission 60 new facilities in FY '27, with a balanced mix of surgical centers and clinics. The call concluded with a discussion on the merger process with Dr. Agarwal's Eye Hospital Limited, which is progressing through regulatory approvals.

Key takeaway: The investor presentation from Dr. Agarwal's Health Care Limited detailed the company's audited financial results for the quarter and year ended March 31, 2026. The presentation highlighted a total income of ₹2,125 crore, reflecting a year-on-year growth rate of 20.9%. EBITDA was reported at ₹614 crore, with a growth rate of 22.2%, while profit after tax reached ₹168 crore, marking a significant increase of 52.4%. The company expanded its network by adding 57 facilities during FY26, bringing the total to 288 eye care facilities. The presentation also emphasized the company's operational strengths, including a diversified presence across 155 cities and a focus on clinical excellence. Management noted the importance of their hub-and-spoke model in enhancing accessibility and efficiency. Additionally, the eye care industry in India was described as having substantial growth potential, with Dr. Agarwal's positioned as a leading player in this market.

Key takeaway: Dr. Agarwal's Health Care Limited reported strong financial performance for the nine months ended December 31, 2025, with total income increasing by 20.8% year-on-year to Rs.1,548 crores and revenue from operations rising by 21.2% to Rs.1,516 crores. The company achieved an IndAS EBITDA of Rs.440 crores, reflecting a 23.6% growth, and profit after tax grew by 74.3% to Rs.118 crores. In Q3 alone, total income was Rs.540 crores, up 21.9% year-on-year, with a profit after tax of Rs.44 crores, a 55% increase. The company expanded its network to 253 facilities across India, serving over 22 lakh patients and performing nearly 238,283 surgeries. Management highlighted growth in high-end cataract surgeries and continued investment in new facilities and advanced technologies. The earnings call included discussions on regional performance, operational efficiency, and future expansion plans.

Key takeaway: The investor presentation from Dr. Agarwal's Health Care Limited detailed the company's unaudited financial results for the quarter and nine months ended December 31, 2025. The presentation highlighted a total income of ₹1,548 crore, reflecting a year-on-year growth rate of 20.8%. EBITDA was reported at ₹440 crore, with a growth rate of 23.6%, while profit after tax reached ₹118 crore, marking a significant increase of 74.3%. The company expanded its network by adding 38 facilities year-to-date, bringing the total to 272 eye care facilities. The presentation emphasized the company's operational excellence, clinical innovations, and a strong focus on attracting and retaining qualified medical professionals. Management noted the importance of their hub-and-spoke model in enhancing accessibility and efficiency across their services. The document also included disclaimers regarding the information provided and the nature of forward-looking statements.